WO2017110716A1 - Article absorbant - Google Patents

Article absorbant Download PDF

Info

Publication number
WO2017110716A1
WO2017110716A1 PCT/JP2016/087722 JP2016087722W WO2017110716A1 WO 2017110716 A1 WO2017110716 A1 WO 2017110716A1 JP 2016087722 W JP2016087722 W JP 2016087722W WO 2017110716 A1 WO2017110716 A1 WO 2017110716A1
Authority
WO
WIPO (PCT)
Prior art keywords
absorbent
absorbent sheet
sheet
blood
polymer
Prior art date
Application number
PCT/JP2016/087722
Other languages
English (en)
Japanese (ja)
Inventor
剛大 石川
木村　真由美
耕裕 山本
佑佳 鈴木
繁宏 松原
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2016111716A external-priority patent/JP6279014B2/ja
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN201680069797.8A priority Critical patent/CN108366892B/zh
Publication of WO2017110716A1 publication Critical patent/WO2017110716A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A61F13/535—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A61F13/537—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad characterised by a layer facilitating or inhibiting flow in one direction or plane, e.g. a wicking layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments

Definitions

  • the present invention relates to an absorbent article.
  • Patent Document 1 discloses a menstrual band including an absorbent pad containing a salt of multivalent ions.
  • Patent Document 2 discloses a napkin containing a partially hydrated dicarboxylic anhydride copolymer or polycation as a blood gelling agent.
  • Patent Document 3 proposes a personal care absorbent article containing a triblock polymer or polycation containing polypropylene oxide and polyethylene oxide as a fluid treatment material.
  • the present invention relates to an absorbent article capable of absorbing blood, comprising an absorbent containing a superabsorbent polymer, hydrophilic fibers and a blood coagulant, and a front sheet and a back sheet sandwiching the absorbent.
  • the absorbent body has a polymer-rich region in which the mass ratio of the superabsorbent polymer to the total mass of the hydrophilic fiber and the superabsorbent polymer is relatively high in a cross-sectional view, and the polymer-rich region. And a hydrophilic fiber rich region relatively lower than the region.
  • the blood coagulant is present more in the polymer rich region than in the hydrophilic fiber rich region.
  • FIG. 1 is a plan view of a sanitary napkin which is a preferred embodiment of the absorbent article for menstrual absorption of the present invention.
  • FIG. 2 is a plan view showing the skin facing surface side (surface sheet side) of the absorbent body of the sanitary napkin shown in FIG. 3 is a cross-sectional view schematically showing a cross section taken along line III-III in FIG.
  • FIG. 4 is an enlarged cross-sectional view of an absorbent body included in the sanitary napkin shown in FIG.
  • FIG. 5 is an enlarged schematic cross-sectional view of a main part of one absorbent sheet constituting the absorbent body shown in FIG.
  • Drawing 6 is an expanded sectional view of an absorber of other embodiments with which an absorptive article of the present invention is provided.
  • FIG. 7 is an enlarged cross-sectional view of an absorbent body according to still another embodiment provided in the absorbent article of the present invention.
  • Patent Documents 1 and 4 do not describe any structure for improving the blood absorption rate except that a water-soluble metal compound is used as a blood coagulant.
  • a water-soluble metal compound is used as a blood coagulant.
  • the absorbent articles described in Patent Literature 2 and Patent Literature 3 describe that a fluid treatment agent containing a polycation can be used, only data on nonionic treatment materials is actually disclosed.
  • the techniques disclosed in these documents take time to absorb blood, and are disadvantageous in terms of so-called liquid return in which blood returns to the skin side when worn.
  • an object of the present invention is to provide an absorbent article that can eliminate the above-mentioned drawbacks of the prior art.
  • FIG. 1 shows a plan view of a napkin which is a preferred embodiment of the absorbent article for menstrual absorption of the present invention
  • FIG. 2 shows the skin of the absorbent body 4 shown in FIG.
  • the top view which shows an opposing surface side (surface sheet side) is shown.
  • FIG. 3 shows a cross-sectional view of the napkin 1 of the present embodiment.
  • the napkin 1 includes a liquid-permeable surface sheet 2 that forms a skin facing surface, a back sheet 3 that forms a non-skin facing surface, and both of these sheets 2 and 3. It has an absorbent main body 10 having an absorbent body 4 interposed between them and made of an absorbent sheet containing pulp 42 and blood coagulant 43.
  • the absorbent main body 10 of the napkin 1 is a wearer than the excretion part facing part B, which is disposed opposite to the excretion part (vagina mouth or the like) of the wearer when worn, and the wearer facing part B.
  • the front part A is arranged closer to the stomach side (front side) and the rear part C is arranged closer to the wearer's back side (rear side) than the excretory part facing part B.
  • the napkin 1 and the absorbent main body 10 have a longitudinal direction X corresponding to the wearer's front-rear direction and a transverse direction Y orthogonal to the longitudinal direction X. That is, the absorbent main body 10 is divided in the order of the front part A, the excretory part opposing part B, and the rear part C in the vertical direction X.
  • a skin opposing surface is a surface in the napkin 1 or its component (for example, surface sheet 2) orient
  • a non-skin opposing surface is a napkin. 1 or a component thereof, which is a surface directed to the side opposite to the skin side (clothing side) when the napkin 1 is worn.
  • the longitudinal direction X coincides with the longitudinal direction of the napkin 1 and the absorbent main body 10
  • the lateral direction Y coincides with the width direction (direction orthogonal to the longitudinal direction) of the napkin 1 and the absorbent main body 10.
  • the napkin 1 is further laterally extended from both side portions along the longitudinal direction X of the excretory part-facing portion B of the absorbent main body 10 in addition to the absorbent main body 10. It has a pair of wing parts 10W and 10W extending outward of Y.
  • the longitudinal direction of the absorbent article (the longitudinal direction of the absorbent article, FIG. (X direction in the middle) means a region having a wing portion 10W (a region sandwiched between a root along the vertical direction X of one wing portion 10W and a root along the vertical direction X of the other wing portion 10W).
  • the excretion part opposing part B in the absorbent article which does not have a wing part is produced when the absorbent article is folded into a three-fold individual packaging form. With respect to two folding curves (not shown) crossing in the Y direction in the middle, it means a region surrounded by the first folding curve and the second folding curve counted from the front end in the longitudinal direction X of the absorbent article. To do.
  • the top sheet 2 covers the entire area of the skin facing surface of the absorbent body 4 as shown in FIG. 1, and the outer side in the lateral direction Y from both side edges along the longitudinal direction X of the absorbent body 4. It extends to the direction.
  • the back sheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4 and further extends outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorbent body 4 to be described later.
  • a side flap portion 10S is formed.
  • top sheet 2 and the back sheet 3 are joined to each other by known joining means such as an adhesive, heat seal, ultrasonic seal, and the like, at portions extending from both end edges in the longitudinal direction X of the absorber 4.
  • joining means such as an adhesive, heat seal, ultrasonic seal, and the like, at portions extending from both end edges in the longitudinal direction X of the absorber 4.
  • between each of the top sheet 2 and the back sheet 3 and the absorbent body 4 may be joined by an adhesive.
  • the side sheets 7 are disposed on both sides along the longitudinal direction X of the skin facing surface of the absorbent main body 10 (skin facing surface of the top sheet 2).
  • the side sheet 7 is arranged over the entire length in the longitudinal direction X of the absorbent main body 10 so as to overlap the left and right side portions along the longitudinal direction X of the absorbent body 4 in plan view.
  • the pair of side sheets 7 and 7 each have a linear first joining line 61 located in the excretory part facing part B and the longitudinal direction X of the first joining line 61.
  • the first joint line 61 is a curved line convex outward in the lateral direction Y in plan view
  • the second joint line 62 is a line (zigzag) extending so as to alternately intersect the vertical direction in plan view. Linear).
  • a space P defined by the side sheet 7 and the top sheet 2 is formed inward in the lateral direction Y with respect to the first joint line 61 and the second joint line 62. Since the space P is opened toward the center in the lateral direction Y of the absorbent main body 10, body fluid such as menstrual blood flowing outward from the center in the lateral Y is accommodated in the space P. As a result, leakage of body fluid can be effectively prevented.
  • a pair of leak-proof cuffs along the vertical direction X may be arranged by disposing an elastic member extending in the vertical direction X at the free ends of the pair of side sheets 7, 7.
  • the leak-proof cuff has an upright property and can prevent the side leakage of menstrual blood disposed on the skin facing surface.
  • the side flap part 10S protrudes greatly outward in the lateral direction Y at the excretory part facing part B, and thereby the left and right along the longitudinal direction X of the absorbent main body 10
  • a pair of wing portions 10W and 10W are extended on both sides.
  • the top sheet 2 and the back sheet 3 extend outward in the longitudinal direction X from the front end and the rear end in the longitudinal direction X of the absorbent body 4.
  • the end seal portion is formed by bonding to each other by a known bonding means such as an agent, heat sealing, ultrasonic sealing or the like.
  • the wing part 10W is used by being folded back to the non-skin facing surface side of the crotch part of clothes such as shorts.
  • the wing portion 10 ⁇ / b> W has a substantially trapezoidal shape in which a lower base (a side longer than the upper base) is located on a side portion along the longitudinal direction X of the absorbent main body 10 in a plan view, as shown in FIG. 1. It has a shape.
  • a wing portion adhesive portion (not shown) for fixing the wing portion 10W (napkin 1) to clothes (not shown) such as shorts is formed on the non-skin facing surface of the wing portion 10W.
  • the wing portion 10W folded back to the non-skin facing surface (outer surface) side of the crotch portion of the clothes can be adhesively fixed to the crotch portion by the adhesive portion during use.
  • the main body adhesion part (not shown) for fixing the absorptive main body 10 to clothes, such as shorts, is also formed in the non-skin opposing surface of the absorptive main body 10.
  • the napkin 1 is provided with a second sheet 5 made of a nonwoven fabric between the top sheet 2 and the absorbent body 4.
  • the second sheet 5 covers substantially the entire skin facing surface of the absorbent body 4 in the napkin 1.
  • the second sheet 5 is a sheet called a sublayer sheet in the technical field, which is a separate body from the top sheet 2 and the absorber 4.
  • the second sheet 5 is a sheet that plays a role of improving the liquid permeability from the top sheet 2 to the absorber 4 or reducing the return of the liquid absorbed by the absorber 4 to the top sheet 2.
  • the second sheet 5 is a sheet that does not contain a blood coagulant 43 described later.
  • FIG. 4 shows an enlarged cross-sectional view of the absorber 4 in the cross-sectional view shown in FIG. Moreover, the principal part expanded sectional view of one absorbent sheet which comprises the absorber 4 shown in FIG. 4 is shown by FIG.
  • the absorbent body 4 made of an absorbent sheet is composed of a superabsorbent polymer 41 dispersed in three dimensions, a pulp 42 as a hydrophilic fiber that fixes the superabsorbent polymer 41, and blood aggregation. Agent 43.
  • the absorbent sheet has a polymer-rich region PT having a relatively high mass ratio of the superabsorbent polymer 41 to the total mass of the pulp 42 and the superabsorbent polymer 41 in a cross-sectional view, It has a pulp rich region FT as a hydrophilic fiber rich region that is relatively lower than the polymer rich region PT.
  • the polymer rich region PT and the pulp rich region FT are divided in the thickness direction of the absorbent sheet.
  • the absorbent body 4 made of an absorbent sheet includes pulp 42 and has an integral structure in which a superabsorbent polymer 41 and a blood coagulant 43 are contained.
  • seat is an absorber currently shape
  • Typical examples of the absorbent sheet include those described in Japanese Patent No. 2963647 and those described in Japanese Patent No. 2955223.
  • the superabsorbent polymer 41 possessed by the absorbent body 4 particles are generally used, but fibers may be used.
  • the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape.
  • a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof.
  • sodium salts can be preferably used.
  • hydrophilic fiber possessed by the absorbent body 4 examples include those obtained by hydrophilizing hydrophobic fibers and those that are hydrophilic per se. In particular, those which are hydrophilic per se and have water retention properties are preferable since the effects of the present invention are further exhibited.
  • Preferred examples of the latter hydrophilic fibers include natural fibers, cellulosic regenerated fibers, and semi-synthetic fibers.
  • pulp and rayon are particularly preferable, and pulp is more preferable.
  • pulp 42 is used as the hydrophilic fiber.
  • a bulky cellulose fiber obtained by mercerizing a crosslinked cellulose fiber or wood pulp in which cellulose fibers are intermolecularly and / or intermolecularly crosslinked may be used.
  • the pulp 42 include, but are not limited to, wood pulp such as coniferous kraft pulp or hardwood kraft pulp, natural cellulose fibers such as cotton pulp or straw pulp, and the like. These pulps can be used alone or in combination of two or more.
  • the absorbent article of the present invention includes a blood aggregating agent 43 in the absorbent body 4.
  • the blood aggregating agent used in the present invention is one that aggregates erythrocytes in blood to form erythrocyte aggregates and can be separated from plasma components, and preferably has the following properties. That is, when 1000 ppm of the measurement sample agent is added to the simulated blood, at least two or more red blood cells aggregate to form an aggregate while maintaining the fluidity of the blood.
  • the simulated blood has a viscosity of 8 mPa ⁇ s measured using a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds).
  • the blood cell / plasma ratio of defibrinated horse blood was prepared.
  • the state in which the fluidity of blood is maintained means that 10 g of the simulated blood to which 1000 ppm of the measurement sample agent is added is a screw tube (product number “Screw tube No. 4” manufactured by Marum Co., Ltd.). 5 mm, body diameter 27 mm, total length 55 mm), and when the screw tube bottle containing the simulated blood is inverted 180 degrees, the simulated menstrual blood of a volume of 60% or more flows down within 20 seconds. Further, whether or not “two or more red blood cells aggregate to form an aggregate” is determined as follows.
  • the simulated blood to which the measurement sample agent was added at 1000 ppm was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (manufactured by HORIBA, Inc., model number: LA-950V2, measurement condition: flow type cell).
  • the average median diameter of the volume particle diameter measured at a temperature of 25 ° C. by a laser diffraction scattering method using a measurement, a circulation speed of 1 and no ultrasonic wave corresponds to the size of an aggregate in which two or more red blood cells are aggregated. When it is 10 ⁇ m or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.
  • the blood aggregating agent 43 included in the absorber 4 includes a cationic polymer.
  • the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride.
  • the blood coagulant 43 can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer.
  • the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization.
  • the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things.
  • the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.
  • the blood agglutinating agent 43 includes a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer
  • the blood aggregating agent 43 is , Quaternary ammonium salt homopolymer, quaternary ammonium salt copolymer and quaternary ammonium salt polycondensate may be included, or any combination of two or more may be included. You may go out.
  • a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types.
  • the quaternary ammonium salt copolymer can be used alone or in combination of two or more.
  • a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types.
  • the “blood aggregating agent” is a compound capable of aggregating blood erythrocytes or a combination thereof, and further an agent that expresses erythrocyte aggregation by a combination of compounds. That is, the blood aggregating agent is an agent limited to those having a hemagglutinating action. Therefore, when the blood coagulant contains the third component, it is expressed as a blood coagulant composition and is distinguished from the blood coagulant.
  • quaternary ammonium salt polymer a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate
  • quaternary ammonium salt polymer a quaternary ammonium salt polymer that is quaternary ammonium salt of a quaternary ammonium salt in a quaternary ammonium salt in a quaternary ammonium salt in a quaternary ammonium salt polycondensate.
  • the quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing two or more condensates having two or more monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.
  • the quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety.
  • a quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent.
  • the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce
  • the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate.
  • dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur.
  • the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. .
  • a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized.
  • Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.
  • Red blood cells have a red blood cell membrane on their surface.
  • the erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer.
  • the lipid film exposed on the surface of erythrocytes contains a protein called glycophorin.
  • Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end.
  • erythrocytes can be treated as colloidal particles having an anionic charge.
  • an aggregating agent is used for aggregating the colloidal particles.
  • erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes.
  • the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes.
  • the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups.
  • the cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more.
  • the upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less.
  • the molecular weight of the cationic polymer is preferably 2000 or more and 10 million or less, more preferably 2000 or more and 5 million or less, still more preferably 2000 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferably 30,000 to 3,000,000.
  • the molecular weight referred to in the present invention is a weight average molecular weight.
  • the molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions.
  • the molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows.
  • a column a column in which a guard column ⁇ and an analytical column ⁇ -M manufactured by Tosoh Corporation are connected in series is used at a column temperature of 40 ° C.
  • the detector uses RI (refractive index).
  • 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 ⁇ L.
  • Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 ⁇ L.
  • the quaternary ammonium salt polymer has a flow potential of 1500 ⁇ eq / L or more from the viewpoint of more effectively generating red blood cell aggregates. , More preferably 2000 ⁇ eq / L or more, still more preferably 3000 ⁇ eq / L or more, still more preferably 4000 ⁇ eq / L or more.
  • the flow potential of the quaternary ammonium salt polymer is not less than these values, the electric double layer of erythrocytes can be sufficiently neutralized.
  • the upper limit of the streaming potential is preferably 13000 ⁇ eq / L or less, more preferably 8000 ⁇ eq / L or less, and even more preferably 6000 ⁇ eq / L or less.
  • the streaming potential of the quaternary ammonium salt polymer is preferably 1500 ⁇ eq / L or more and 13000 ⁇ eq / L, more preferably 2000 ⁇ eq / L or more and 13000 ⁇ eq / L or less, and 3000 ⁇ eq / L or more and 8000 ⁇ eq / L or less. Is more preferably 4000 ⁇ eq / L or more and 6000 ⁇ eq / L or less.
  • the flow potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituting cationic monomer itself, and the copolymerization molar ratio of the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. Can be controlled.
  • the streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. Specific measurement conditions are as follows. First, a commercially available napkin is heated using a dryer or the like to invalidate the hot melt bonding each member, and is decomposed into members such as a top sheet, an absorber, and a back sheet.
  • a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent is performed to separate the treating agent used in each member to obtain a solution containing a single composition.
  • the obtained solution was dried and solidified, and 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel) Permeation chromatography) and fluorescent X-rays are combined to identify the structure of the treatment agent.
  • the cationic polymer In order for the cationic polymer to be successfully adsorbed on the surface of red blood cells, it is advantageous that the cationic polymer easily interacts with sialic acid present on the surface of red blood cells. From this point of view, the present inventors proceeded with studies, and as a result, inorganic value / organic value (hereinafter referred to as “IOB (Inorganic Organic Balance) value”), which is the ratio between the inorganic value and the organic value of the substance. It was found that the degree of interaction between the sialic acid conjugate and the cationic polymer can be evaluated on the basis of. Specifically, it has been found advantageous to use a cationic polymer having an IOB value that is the same as or close to that of the sialic acid conjugate.
  • the sialic acid conjugate is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as galactolipid.
  • the properties of a substance are largely controlled by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Wals force due to molecular mass and electric affinity due to the polarity of the molecule. If the Van Der Waals force, which has a great influence on changes in the properties of substances, and the electrical affinity can be grasped individually, the properties of unknown substances or their mixtures can be predicted from the combination. be able to.
  • This idea is a theory well known as “organic conceptual diagram”.
  • Conceptual diagram of organic materials is, for example, “Organic analysis” written by Kei Fujita (Kanya Shoten, Showa 5), “Organic qualitative analysis: Systematic.
  • the degree of physical properties due to Van Der Waals force is called ⁇ organic ''
  • the degree of physical properties mainly due to electrical affinity is called ⁇ inorganic ''
  • the physical properties of substances are considered as a combination of “organic” and “inorganic”.
  • one carbon (C) is defined as organic 20
  • the inorganic and organic values of various polar groups are defined as shown in Table 1 below. The sum of the values is obtained, and the ratio between the two is defined as the IOB value.
  • the IOB value of the sialic acid conjugate described above is determined based on these organic and inorganic values
  • the IOB value of the cationic polymer is determined based on the value.
  • the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated.
  • the IOB value is calculated according to the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from monomer A and monomer B, the organic value of monomer A is ORA, the inorganic value is INA, the organic value of monomer B is ORB, and the inorganic value is INB. Yes, when the molar ratio of monomer A / monomer B is MA / MB, the IOB value of the copolymer is calculated from the following equation.
  • the IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, 2.2 It is still more preferable that it is above. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. More preferably, it is 2.2 or more and 3.0 or less.
  • the IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate.
  • the sialic acid conjugate is a glycolipid in which a sugar chain in a glycolipid and sialic acid are bound, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than sialic acid alone.
  • the organic value itself is preferably 40 or more, more preferably 100 or more, and even more preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, still more preferably 240 or less, and even more preferably 190 or less.
  • the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, still more preferably 100 or more and 240 or less, and still more preferably 130 or more and 190 or less.
  • the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, still more preferably 100 or more, still more preferably 120 or more, and 250 or more. It is particularly preferred that Further, it is preferably 790 or less, more preferably 750 or less, still more preferably 700 or less, still more preferably 680 or less, and particularly preferably 490 or less.
  • the asexual value is preferably 70 or more and 790 or less, more preferably 90 or more and 750 or less, still more preferably 90 or more and 680 or less, and still more preferably 120 or more and 680 or less, It is especially preferable that it is 250-490. By setting the inorganic value of the cationic polymer within this range, the cationic polymer can be more effectively adsorbed to erythrocytes.
  • x and y satisfy the following formula A when the organic value of the cationic polymer is x and the inorganic value is y.
  • y ax (A)
  • a is preferably 0.66 or more, more preferably 0.93 or more, and even more preferably 1.96 or more.
  • a is preferably 4.56 or less, more preferably 4.19 or less, and even more preferably 3.5 or less.
  • a is preferably a number from 0.66 to 4.56, more preferably from 0.93 to 4.19, and a number from 1.96 to 3.5. Is more preferable.
  • the organic value and the inorganic value of the cationic polymer satisfy the above formula A, provided that the organic value and the inorganic value of the cationic polymer are within the above-mentioned ranges, the cation The functional polymer is likely to interact with the sialic acid conjugate, and the cationic polymer is more easily adsorbed to erythrocytes.
  • the cationic polymer is preferably water-soluble.
  • water-soluble means that 0.05 g of a 1 mm or less powdery or 0.5 mm or less film-like cationic polymer is added to a 100 mL glass beaker (5 mm ⁇ ) and mixed with 50 mL ion-exchange water at 25 ° C.
  • a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd.
  • the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.
  • the cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium moiety is preferably present in the side chain.
  • the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs.
  • bonded at one point means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain.
  • Connected at two or more points means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain.
  • a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto.
  • the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more.
  • the upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less.
  • the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less.
  • the carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included.
  • the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is in the above range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer
  • examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety.
  • a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization are examples of the homopolymer.
  • alkylating agent and the acid are as described above.
  • the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.
  • quaternary ammonium salt homopolymer examples include polyethyleneimine.
  • examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer
  • two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer.
  • a copolymer obtained by the above copolymerization can be used.
  • the quaternary ammonium salt copolymer one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety
  • the copolymer obtained by copolymerizing using 1 or more types of bodies can be used.
  • the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.
  • the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer
  • charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated.
  • Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine.
  • Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropane sulfonic acid, methacrylic acid, acrylic acid, styrene sulfonic acid, and salts of these compounds.
  • nonionic polymerizable monomers examples include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl Examples include acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate.
  • One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do.
  • a quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly preferably 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).
  • a polymerizable monomer having a functional group capable of hydrogen bonding can also be used.
  • a polymerizable monomer having a functional group capable of hydrogen bonding include —OH, —NH 2, —CHO, —COOH, —HF, —SH and the like.
  • polymerizable monomers having functional groups capable of hydrogen bonding examples include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, Examples thereof include hydroxyethyl methacrylate and hydroxyethyl acrylate.
  • hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used.
  • a polymerizable monomer for copolymerization By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced.
  • functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups.
  • polymerizable monomers having functional groups capable of hydrophobic interaction examples include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned.
  • methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc. which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer. Or it is preferable to adjust so that the streaming potential of a quaternary ammonium salt copolymer may become the value mentioned above. Or it is preferable to adjust so that IOB of a quaternary ammonium salt copolymer may become the value mentioned above.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and even more preferably 56 mol% or less.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, More preferably, it is 32 mol% or more and 65 mol% or less, and more preferably 38 mol% or more and 56 mol% or less.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate
  • a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used as the polycondensate.
  • Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.
  • the above-described quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or copolymerization method of a vinyl polymerizable monomer.
  • the polymerization method for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.
  • the cationic polymer described in detail above is an example of the above-mentioned “preferable blood coagulant 43”, and the effect thereof can be referred to in Examples 1 to 45 of Japanese Patent Application No. 2015-239286.
  • the blood aggregating agent 43 of the absorbent body 4 is a third component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. And the like (blood aggregating agent composition).
  • a solvent such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. And the like (blood aggregating agent composition).
  • components other than the cationic polymer that can be included in the blood aggregating agent 43 can be used alone or in combination.
  • the solvent water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used.
  • glycerin polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used.
  • flavor the fragrance
  • an antibacterial / deodorant it is polymerized from a cancrinite-like mineral containing a metal having antibacterial properties described in Japanese Patent No. 4526271, and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928. Porous polymers, quaternary ammonium salts, activated carbon, clay minerals and the like described in Japanese Patent No. 4651392 can be used.
  • the skin care agent plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.
  • the proportion of the cationic polymer in the blood aggregating agent composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less.
  • the proportion of the cationic polymer is preferably 1% by mass to 50% by mass, more preferably 3% by mass to 30% by mass, and even more preferably 5% by mass to 10% by mass. preferable.
  • the amount of the blood aggregating agent 43 contained in the absorbent sheet constituting the absorbent body 4 is preferably 0.1 g / m 2 or more, more preferably 0.5 g / m 2 or more. More preferably, it is 5 g / m 2 or more. Further, it is preferably 25 g / m 2 or less, more preferably 15 g / m 2 or less, and even more preferably 10 g / m 2 or less.
  • the amount of the blood coagulant 43 is preferably 0.1 g / m 2 or more and 25 g / m 2 or less, more preferably 0.5 g / m 2 or more and 15 g / m 2 or less, and more preferably 1.5 g / m 2. it is more preferred m 2 or more and 10 g / m 2 or less.
  • the amount is It is the sum total of the blood coagulant 43 applied to the site. It is particularly preferable that the blood coagulant 43 is a cationic polymer and the amount of the cationic polymer contained in the absorbent sheet is in the above range.
  • the absorbent body 4 has a multilayer structure formed of an absorbent sheet as shown in FIGS.
  • the formed multilayer structure may be formed by overlapping a plurality of absorbent sheets, or may be formed by folding a single absorbent sheet. However, it may be formed by combining these.
  • the absorbent body 4 includes, as shown in FIGS. 3 and 4, a central absorbent sheet 402 formed of an absorbent sheet on the excretory part facing part B that is disposed to face the excretion part of the wearer when worn.
  • the main body absorbent sheet 401 covers the central absorbent sheet 402.
  • the absorbent body 4 of the napkin 1 has a multilayer structure formed of the main body absorbent sheet 401 and the central absorbent sheet 402, and forms a middle-high part 403 in the excretory part facing part B.
  • the multilayer structure of the absorbent body 4 of the napkin 1 has a structure in which a central absorbent sheet 402 is included in the folded structure of one main body absorbent sheet 401, and the central absorbent sheet 402 is formed in the middle and high portions 403. It is arranged.
  • the main body absorbent sheet 401 is composed of one sheet having a length (width) in the lateral direction Y longer than that of the napkin 1, and the main body absorbent sheet 401 Of the absorbent sheet 401 is folded back to the back sheet 3 side to form a two-layer structure, and both side edges along the vertical direction X are overlapped at the center in the horizontal direction Y, The outer shape is formed.
  • the main body absorbent sheet 401 which forms a two-layer structure has the surface side absorbent sheet 401a by the side of the surface sheet 2, and the back surface side absorbent sheet 401b by the side of the back sheet 3.
  • the central absorbent sheet 402 is composed of a single sheet having a rectangular shape in plan view, and has a three-layer structure in which the central absorbent sheet 402 is folded in three in the lateral direction Y.
  • the central absorbent sheet 402 has a three-layer structure, in the two fold lines crossing the central absorbent sheet 402 in the longitudinal direction X, the second fold line counted from the free end in the lateral direction Y is used. Bend to the back sheet 3 side, and then bend to the top sheet 2 side at the first fold line counted from the free end in the lateral direction Y so that the free end in the lateral direction Y is arranged inside the three-layer structure Fold it in a spiral.
  • the central absorbent sheet 402 that forms a three-layer structure folded in a spiral shape includes an upper absorbent sheet 402a on the front surface side absorbent sheet 401a side and a lower absorbent sheet on the back surface side absorbent sheet 401b side. 402b and an intermediate absorbent sheet 402c between the sheets 402a and 402b.
  • the middle-high portion 403 is formed by sandwiching a sheet having a three-layer structure including an upper absorbent sheet 402a, an intermediate absorbent sheet 402c, and a lower absorbent sheet 402b between the front side absorbent sheet 401a and the rear side absorbent sheet 401b. Has been.
  • the middle-high part 403 is formed only in the excretion part facing part B, and is not formed in the front part A and the rear part C. As shown in FIG. 4, the number of laminated absorbent sheets constituting the absorber 4 around the middle-high portion 403 is two, whereas the number of laminated absorbent sheets constituting the absorber 4 in the middle-high portion 403. However, the number of laminated sheets is large and the thickness is large. For this reason, the middle-high part 403 is a raised part that protrudes from the excretory part facing part B to the topsheet 2 side (skin facing side of the napkin 1).
  • the thickness per absorbent sheet is preferably 0.1 mm or more, particularly 0.3 mm or more, and preferably 2 mm or less, particularly 1.5 mm or less. More specifically, it is 0.1 mm or more and 2 mm or less, particularly 0.3 mm or more and 1.5 mm or less to obtain an absorbent article having sufficient liquid diffusibility and liquid retention and having a good wearing feeling. It is preferable from the point.
  • the absorber 4 has a thickness at the middle-high portion 403 of preferably 0.7 mm or more, more preferably 1 mm or more, preferably 5 mm or less, more preferably 4 mm or less, more specifically preferably It is 0.7 mm or more and 5 mm or less, More preferably, it is 1 mm or more and 4 mm or less.
  • the thickness of the absorber other than the middle-high portion 403 is preferably 0.3 mm or more, more preferably 0.5 mm or more, and preferably 3 mm or less, more preferably 2.5 mm or less, More specifically, it is preferably 0.3 mm or more and 3 mm or less, more preferably 0.5 mm or more and 2.5 mm or less. This range is preferable from the viewpoint of enhancing the high absorption performance and the ability to follow the wearer's movement.
  • the thickness of an absorber and an absorptive sheet is measured by the following method.
  • the absorbent sheet or absorbent body which is the measurement object, is placed in a horizontal place so as not to be wrinkled or bent, and the thickness under a load of 5 cN / cm 2 is measured.
  • a thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) was used for measuring the thickness in the present invention.
  • a circular plate or a square plate (acrylic plate having a thickness of about 5 mm) in plan view is disposed between the tip of the thickness meter and the measurement portion of the measurement object, and the load is 5 cN / cm 2 . Adjust the size of the plate so that
  • the blood coagulant 43 is present more in the polymer rich region PT than in the pulp rich region FT, as shown in FIG.
  • “existingly” means that the mass of the blood coagulant 43 present per area of each region FT, PT, that is, the basis weight of the blood coagulant 43 in each region FT, PT is compared. This means that the basis weight of the blood coagulant 43 in one region is relatively large.
  • the blood aggregating agent 43 is present more in the polymer rich region PT than in the pulp rich region FT in the portion where the pulp rich region FT is disposed on the skin facing surface side.
  • the blood coagulant 43 is present more in the polymer rich region PT than in the pulp rich region FT.
  • the absorbent body 4 has a multilayer structure formed of an absorbent sheet like the napkin 1, even if the blood aggregating agent 43 is not disposed on all the absorbent sheets forming the multilayer structure. Good.
  • the blood aggregating agent 43 is disposed on the central absorbent sheet 402 that forms a three-layer structure including an upper absorbent sheet 402a, an intermediate absorbent sheet 402c, and a lower absorbent sheet 402b. Has been.
  • the central absorbent sheet 402 has a three-layer structure that is folded in three
  • the upper absorbent sheet 402a and the intermediate absorbent sheet 402c each have a pulp-rich region FT on the skin facing surface.
  • the lower absorbent sheet 402b is used with the pulp rich region FT arranged on the non-skin facing surface side. Accordingly, in the middle-high portion 403, the surface side absorbent sheet 401a, the upper side absorbent sheet 402a, and the intermediate absorbent sheet 402c are all in the order of the pulp rich region FT and the polymer rich region PT when viewed from the skin contact surface side.
  • the polymer rich region PT and the pulp rich region FT are arranged in this order as viewed from the skin contact surface.
  • the blood aggregating agent 43 is present in the polymer rich region PT and the pulp rich region FT. More of the polymer rich region PT than the pulp rich region FT.
  • a blood coagulant 43 exists in the polymer rich region PT and the pulp rich region FT, and exists more in the polymer rich region PT than in the pulp rich region FT.
  • the surface side absorbent sheet 401a closest to the surface sheet 2 is used with the pulp rich region FT disposed on the skin facing surface side, but the blood aggregating agent 43 is not disposed.
  • the back side absorbent sheet 401b closest to the back side sheet 3 is used with the pulp rich region FT disposed on the non-skin facing surface side, but the blood aggregating agent 43 is not disposed.
  • the blood aggregating agent 43 is disposed on the central absorbent sheet 402 that forms a three-layer structure including an upper absorbent sheet 402a, an intermediate absorbent sheet 402c, and a lower absorbent sheet 402b.
  • flocculant 43 is not distribute
  • Whether or not the blood coagulant 43 is disposed is determined as follows. Using an energy dispersive X-ray analyzer (EDX) attached to a scanning electron microscope (SEM), the superabsorbent polymer 41 that the absorber 4 has, the pulp 42 that the absorber 4 has, and the absorber 4 Each elemental analysis of the blood agglutinating agent 43 is performed. Next, a sample piece to be judged as to whether or not the blood agglutinating agent 43 is disposed is attached to an aluminum sample table using a double-sided carbon tape, and after performing platinum / vanadium coating as necessary, SEM observation is performed. The presence or absence of an element in the blood coagulant 43 is checked using EDX (element analysis device) while expanding. The measurement is performed at an acceleration voltage of 15 kV to 40 kV.
  • EDX energy dispersive X-ray analyzer
  • SEM scanning electron microscope
  • whether or not the blood coagulant 43 is present in the polymer rich region PT more than the pulp rich region FT is determined semi-quantitatively as follows.
  • a sample piece comprising an absorbent sheet having a polymer-rich region PT and a pulp-rich region FT and containing a blood aggregating agent 43 is attached to an aluminum sample table using a double-sided carbon tape, and platinum is added if necessary.
  • EDX element analysis device
  • the measurement is performed at an acceleration voltage of 15 kV to 40 kV.
  • the mapping of the element of the blood coagulant 43 is more similar to the mapping of the element of the superabsorbent polymer 41 than the mapping of the element of the pulp 42. It is determined that the flocculant 43 is present more in the polymer rich region PT than in the pulp rich region FT.
  • the absorbent sheet in which the blood coagulant 43 is present in the polymer rich region PT more than the pulp rich region FT is selectively used with respect to the polymer rich region PT in the manufacturing process of the absorbent sheet. It can be created if it contains.
  • the absorbent sheet has a structure in which a pulp rich layer that is a pulp rich region FT and a polymer rich layer that is a polymer rich region PT are overlapped on each of the upper and lower sides, each other layer is created separately, A blood aggregating agent 43 may be included in the polymer rich layer before overlapping with the pulp rich layer.
  • the superabsorbent polymer is dispersed between the fibers by spraying the superabsorbent polymer on a wet fiber web made by wet papermaking with water slurry containing at least hydrophilic fiber and hot melt adhesive fiber or paper strength reinforcing agent.
  • a superabsorbent polymer-rich layer (corresponding to polymer-rich region PT) is formed, and a fiber assembly containing hydrophilic fibers and hot-melt adhesive fibers or paper strength reinforcing agents is layered on top of each other and dried.
  • the fiber aggregate to be overlapped becomes a pulp rich layer (corresponding to the pulp rich region FT).
  • the superabsorbent polymer-rich layer to be superposed contains a blood coagulant in advance, or the absorbent sheet is produced while spraying or coating the coagulant on the superposed polymer-rich layer during the absorbent sheet manufacturing process. By doing so, it becomes possible to make the water-absorbing polymer rich layer contain more blood coagulant than the pulp rich layer.
  • the layer to which the superabsorbent polymer is dispersed is not limited to a wet web, and may be a piled pulp, papermaking, paper produced by drying, or a nonwoven fabric.
  • the fibers of the superabsorbent polymer and the superabsorbent polymer rich layer, and the superabsorbent A hot melt, a water-soluble adhesive, or the like may be used as an adhesion means between the polymer-rich layer and the pulp-rich layer.
  • the pulp rich layer may be formed by stacking or spraying hydrophilic fibers on the superabsorbent polymer rich layer.
  • the flocculant may be sprayed or applied to the pulp rich layer side after the absorbent sheet is manufactured.
  • the blood aggregating agent 43 is unevenly distributed around the superabsorbent polymer 41 in the polymer rich region PT as shown in FIG. That is, in the absorbent body 4, when the position where the distance between the superabsorbent polymers 41, 41 is farthest and the vicinity of at least one of the superabsorbent polymers 41 are compared, the blood aggregating agent 43 is a superabsorbent polymer. There are many in the vicinity of 41. A portion where the blood coagulant 43 does not overlap exists between at least two absorbent sheets adjacent in the thickness direction.
  • the blood aggregating agent 43 is disposed on the central absorbent sheet 402 that forms a three-layer structure including the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b. Yes. As shown in FIG. 4, in the upper absorbent sheet 402a and the intermediate absorbent sheet 402c adjacent in the thickness direction, the superabsorbent polymer 41 and the blood aggregating agent 43 are randomly arranged, and the blood aggregating agent 43 There is a part where does not overlap.
  • the superabsorbent polymer 41 and the blood aggregating agent 43 are randomly arranged, and the portion where the blood aggregating agent 43 does not overlap is present. Existing.
  • the absorbent body 4 is provided with the vertical slit 44 extending in the vertical direction X as shown in FIGS.
  • the longitudinal slit 44 makes it easy for menstrual blood that has reached the absorber 4 to be diffused in the longitudinal direction X and also to penetrate in the thickness direction of the absorber 4.
  • the napkin 1 has a plurality of vertical slits 44, and each slit 44 is arranged in parallel to the vertical direction X.
  • the vertical slits 44 extending in the vertical direction X have slit regions 44 ⁇ / b> S formed so as to be dispersed in both the vertical direction X and the horizontal direction Y. As shown in FIG.
  • the slit region 44 ⁇ / b> S in which the plurality of vertical slits 44 are arranged extends not only to the excretory part facing part B but also to a part of the front part A and a part of the rear part C. That is, the vertical slit 44 exists at least in the excretory part facing part B, and a region including the slit 44 located in the excretion part facing part B is referred to as a slit region 44S.
  • the vertical slit 44 penetrates the absorbent sheet on the most skin-facing surface side including the blood coagulant 43.
  • the most absorbent sheet on the skin-facing surface side including the blood coagulant 43 is the upper absorbent sheet 402a.
  • the vertical slit 44 only has to penetrate only the upper absorbent sheet 402 a. All layers penetrate through the thickness direction.
  • the vertical slit 44 has five laminated sheets constituting the middle-high portion 403 in the excretory part facing part B, that is, the surface side absorbent sheet 401 a, the upper absorbent sheet 402 a, and the intermediate absorbent part.
  • the sheet 402c, the lower side absorbent sheet 402b, and the back side absorbent sheet 401b are all penetrated.
  • the vertical slit 44 penetrates the front side absorbent sheet 401a and the rear side absorbent sheet 401b in a part of the front part A and a part of the rear part C.
  • the arrangement of the vertical slits 44 in the slit area 44S is not particularly limited as long as the vertical slits 44 are distributed in both the vertical direction X and the horizontal direction Y, but the central slit area 44S1 It is preferable that four or more slits are dispersedly arranged.
  • the central slit region 44S1 is a region overlapping with the central absorbent sheet 402 in the slit region 44S. In the central slit region 44S1, it is preferable that three or more slit rows are formed in the longitudinal direction X, more preferably four rows or more, and still more preferably five rows or more.
  • the number of the vertical slits 44 spaced apart in the horizontal direction Y included in each slit row is preferably 2 or more, more preferably 3 or more.
  • the longitudinal direction X of the slit region 44S in addition to the slit rows included in the central slit region 44S1, it is preferable to have one row or two or more slit rows before and after the longitudinal direction X of the central slit region 44S1.
  • the width W44 (see FIG. 2) when each vertical slit 44 is viewed in plan is preferably 0.1 mm or more, more preferably 0.2 mm or more, more preferably 1 mm or less, still more preferably 0.8 mm or less, 0.1 mm or more and 1 mm or less is preferable, and 0.3 mm or more and 0.8 mm or less is more preferable.
  • the length L44 (see FIG. 2) when the vertical slit 44 is viewed in plan is preferably 10 mm or more, more preferably 15 mm or more, and preferably 35 mm or less, more preferably 25 mm or less. And preferably 10 mm or more and 35 mm or less, more preferably 15 mm or more and 25 mm or less.
  • the interval D44 (see FIG. 2) between the vertical slits 44 adjacent to each other in the lateral direction Y is preferably 3 mm or more, more preferably 7 mm or more, and preferably 20 mm or less, more preferably 15 mm or less. Moreover, it is preferably 3 mm or more and 20 mm or less, more preferably 7 mm or more and 15 mm or less.
  • each structural member of the napkin 1 of this embodiment mentioned above is demonstrated.
  • various kinds of materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation.
  • a single layer or multilayer nonwoven fabric, an apertured film, or the like can be used.
  • a moisture-permeable resin film or the like can be used.
  • the second sheet 5 is preferably made of a hydrophilic nonwoven fabric or a hydrophilic fiber assembly.
  • the nonwoven fabric include air-through nonwoven fabric, point bond nonwoven fabric, resin bond nonwoven fabric, spunlace nonwoven fabric, and airlaid nonwoven fabric.
  • the basis weight of the second sheet 5 is preferably 10 g / m 2 or more and 50 g / m 2 or less, and more preferably 15 g / m 2 or more and 40 g / m 2 or less.
  • the thickness of the second sheet 5 is preferably 0.1 mm or more and 5 mm or less.
  • an adhesive is applied and fixed between the top sheet 2 and the second sheet 5, between the second sheet 5 and the absorber 4, and between the absorber 4 and the back sheet 3.
  • the adhesive can be applied using a known means such as a slot coat gun, a spiral spray gun, a spray gun, or a dot gun.
  • the adhesive can be applied in a spiral shape using a spiral spray gun.
  • a hot melt adhesive is preferably used as the adhesive to be applied.
  • the application amount of the hot melt adhesive is preferably 1.5 g / m 2 or more and 10 g / m 2 or less.
  • the laminated body of an absorbent sheet should just be partially cut
  • a cutting device including a cutter roll in which a large number of cutting blades extending in the circumferential direction are dispersed in the circumferential direction and the axial length direction of the roll and an anvil roll that receives the blade of the cutter roll can be used.
  • the absorbent body 4 made of an absorbent sheet includes a polymer-rich region PT having a relatively high amount of the superabsorbent polymer 41 and a relatively superabsorbent polymer 41.
  • the pulp-rich region FT is small, and the blood coagulant 43 is present more in the polymer-rich region PT than in the pulp-rich region FT. Therefore, during use of the napkin 1, menstrual blood is quickly absorbed in the pulp-rich region FT, spot absorption can be performed without spreading the blood, and menstrual blood is converted to red blood cells by the blood aggregating agent 43 in the polymer-rich region PT.
  • the surface side absorbent sheet 401a formed by the main body absorbent sheet 401 containing the blood coagulant 43 is used with the pulp rich region FT disposed on the skin facing surface side. Therefore, menstrual blood is first absorbed in the pulp rich region FT on the skin facing surface side, and menstrual blood is quickly absorbed away from the skin side, and spot absorption can be performed without spreading the blood. Thereafter, menstrual blood is taken over to the polymer-rich region PT, and then hemagglutination and plasma separation occur, and the plasma component is absorbed into the superabsorbent polymer 41. It is difficult to return the liquid.
  • the napkin 1 As shown in FIG.3 and FIG.4, it has the multilayer structure in which the absorber 4 was formed with the absorbent sheet. Therefore, a space is easily formed between each of the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b in which the blood aggregating agent 43 is disposed.
  • the blood cell agglomerates formed in step 1 are less likely to move to the intermediate absorbent sheet 402c and the lower absorbent sheet 402b on the back sheet 3 side, and the plasma of blood tends to increase as it progresses to the back sheet 3 side. It is easy to diffuse in the direction, the absorption rate for absorbing blood is likely to be further increased, and the plasma component is difficult to return to the skin side.
  • the blood aggregating agent 43 is unevenly distributed around the superabsorbent polymer 41 in the polymer rich region PT as shown in FIG. For this reason, the plasma component separated from the blood cell component comes into rapid contact with the superabsorbent polymer 41.
  • the superabsorbent polymer 41 and the blood aggregating agent 43 are randomly arranged, and the blood aggregating agent 43 There is a part where does not overlap.
  • the superabsorbent polymer 41 and the blood aggregating agent 43 are randomly arranged, and the portion where the blood aggregating agent 43 does not overlap is present. Existing. Therefore, the position of the blood cell aggregate formed in each of the upper absorbent sheet 402a, the intermediate absorbent sheet 402c and the lower absorbent sheet 402b is dispersed, and can more effectively absorb menstrual blood, Liquid return becomes more difficult.
  • the absorbent body 4 has a vertical slit 44 in the excretory part facing part B. Therefore, menstrual blood can be easily transferred in the vertical direction X, and the side leakage of menstrual blood can be further prevented. Further, a space is formed in the portion of the absorbent body 4 where the vertical slits 44 are provided so that menstrual blood from the surface sheet 2 can be easily taken in, and menstrual blood can easily enter the thickness direction of the absorbent body 4. Further, menstrual blood easily enters the surface of the absorbent body 4 in the cross section of the vertical slit 44.
  • menstrual blood is easily brought into contact with the blood coagulant 43 present in the absorber 4 and the probability of contact is increased. Therefore, it is considered that the plasma component separated from menstrual blood is easily absorbed by the superabsorbent polymer 41, which is advantageous for suppressing liquid return.
  • the cut portion of the vertical slit 44 is often slightly compressed when cutting, the density is higher than that of the portion where the vertical slit 44 is not provided, and the absorption speed is further increased.
  • the vertical slit 44 completely penetrates the absorber 4, the liquid that has reached the absorber 4 easily reaches the non-skin facing surface side of the absorber 4, and the absorption using the absorber 4 efficiently. This is advantageous from the viewpoint of improving the absorption capacity and suppressing the liquid return.
  • the basic weight of the blood coagulant 43 of the excretory part opposing part B is larger than the basic weight of the blood coagulant 43 of the peripheral part of the excretory part opposing part B It has become. Therefore, menstrual blood can be effectively absorbed by the excretory part facing part B, and the peripheral part of the excretion part facing part B can maintain flexibility, thereby improving the feeling of use.
  • seat 5 comprised by the nonwoven fabric is distribute
  • the blood cell aggregate formed in the absorbent body 4 is covered with the second sheet 5 to prevent the blood cell agglomeration from returning to the surface and making it feel sticky. Can be prevented.
  • the absorbent article of this invention is not restrict
  • the absorbent body 4 has a structure made of an absorbent sheet.
  • the absorbent body structure has a structure in which hydrophilic fibers and / or superabsorbent polymers are stacked.
  • the constitution may be such that the blend ratio of the hydrophilic fiber and the superabsorbent polymer is different between the skin facing surface side and the non-skin facing surface side, and a polymer rich region and a hydrophilic fiber rich region are provided.
  • the blood aggregating agent 43 is added to the central absorbent sheet 402 that forms a three-layer structure including the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b.
  • the blood-flocculant 43 is not arranged on the central absorbent sheet 402, and a two-layer structure composed of a front-side absorbent sheet 401a and a rear-side absorbent sheet 401b is formed.
  • the blood aggregating agent 43 may be disposed on the main body absorbent sheet 401 to be formed. In the absorbent body 4 shown in FIG.
  • the main body absorbent sheet 401 has a two-layer structure in which both side portions along the longitudinal direction X are folded back as described above, and thus the surface-side absorbent sheet on the surface sheet 2 side.
  • 401a is used with the pulp rich region FT disposed on the skin facing surface side
  • the back side absorbent sheet 401b on the back sheet 3 side is disposed with the pulp rich region FT disposed on the non-skin facing surface side.
  • the blood coagulant 43 is present in the polymer rich region PT and the pulp rich region FT, and the pulp rich region It exists more in the polymer rich region PT than in FT.
  • a blood coagulant 43 exists in the polymer rich region PT and the pulp rich region FT, and exists more in the polymer rich region PT than in the pulp rich region FT.
  • the blood coagulant 43 is present in the polymer rich region PT more than in the pulp rich region FT. Even if it is repeated at the same absorption site, it absorbs quickly with the high-absorbency polymer, and thus it has the effect that liquid diffusion hardly occurs.
  • the blood aggregating agent 43 is disposed on the central absorbent sheet 402 that forms a three-layer structure including the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b.
  • a blood aggregating agent 43 may also be disposed on the main body absorbent sheet 401.
  • the front surface side absorbent sheet 401 a formed by the main body absorbent sheet 401 is used with the pulp rich region FT disposed on the skin facing surface side, and the back surface formed by the main body absorbent sheet 401.
  • the side absorbent sheet 401b is used with the pulp rich region FT disposed on the non-skin facing surface side.
  • the blood coagulant 43 is present in the polymer rich region PT and the pulp rich region FT, and the pulp rich region It exists more in the polymer rich region PT than in FT.
  • the back side absorbent sheet 401b in which the pulp rich region FT is used on the non-skin facing surface side in other words, in the back side absorbent sheet 401b used in which the polymer rich region PT is placed on the skin facing surface side, a blood coagulant 43 exists in the polymer rich region PT and the pulp rich region FT, and exists more in the polymer rich region PT than in the pulp rich region FT.
  • the upper absorbent sheet 402a and the intermediate absorbent sheet 402c are respectively used with the pulp rich region FT disposed on the skin facing surface side, and the lower absorbent sheet 402b is used for the non-skinned pulp rich region FT. Used on the opposite side.
  • the blood aggregating agent 43 is present in the polymer rich region PT and the pulp rich region FT. More of the polymer rich region PT than the pulp rich region FT.
  • the lower absorbent sheet 402b in which the pulp-rich region FT is disposed on the non-skin facing surface side in other words, in the lower absorbent sheet 402b in which the polymer-rich region PT is disposed on the skin facing surface side,
  • the flocculant 43 is present in the polymer rich region PT and the pulp rich region FT, and more in the polymer rich region PT than in the pulp rich region FT.
  • the absorbent body 4 shown in FIG. 7 since any of the absorbent sheets 401a, 401b, 402a, 402b, and 402c has the blood aggregating agent 43, the absorption speed for absorbing blood is further increased.
  • the contained blood aggregating agent 43 contains any absorbent sheet 401a.
  • 401b, 402a, 402b, 402c may be the same blood aggregating agent 43 or different blood aggregating agents 43.
  • the absorbent sheet constituting the absorbent body 4 is formed of a two-layer region of a polymer rich region PT and a pulp rich region FT. And if it has the pulp rich area
  • the diffusing means for diffusing menstrual blood in the longitudinal direction X is provided in the excretory part facing part B, but the diffusing means may be omitted.
  • the some slit 44 which the absorber 4 of the napkin 1 has is a slit along the vertical direction X as shown in FIG.1 and FIG.2, it makes an angle with respect to both the vertical direction X and the horizontal direction Y. It may be a slit extending in an oblique direction.
  • the absorbent article for absorbing menstrual blood of the present invention may be a panty liner (cage sheet) or the like in addition to a sanitary napkin.
  • An absorbent article capable of absorbing blood comprising an absorbent containing a superabsorbent polymer, a hydrophilic fiber and a blood coagulant, and a front sheet and a back sheet sandwiching the absorbent,
  • the absorbent body has a polymer-rich region in which the mass ratio of the superabsorbent polymer to the total mass of the hydrophilic fiber and the superabsorbent polymer is relatively high in a cross-sectional view, and the polymer-rich region. Having a hydrophilic fiber-rich region relatively lower than the region, Absorbent article in which the blood coagulant is present more in the polymer rich region than in the hydrophilic fiber rich region.
  • ⁇ 2> The absorbent article according to ⁇ 1>, wherein the absorbent body is made of an absorbent sheet.
  • ⁇ 4> The absorbent article according to any one of ⁇ 1> to ⁇ 3>, wherein the blood coagulant is a cationic polymer.
  • ⁇ 5> The absorbent article according to ⁇ 4>, wherein the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 5> wherein the absorbent body is made of an absorbent sheet and has a multilayer structure in which a plurality of the absorbent sheets are stacked.
  • the absorber is composed of an absorbent sheet, and in the polymer-rich region, the blood aggregating agent is unevenly distributed around the superabsorbent polymer, and at least two of the absorbent sheets adjacent to each other in the thickness direction.
  • the absorbent body is made of an absorbent sheet, and has a longitudinal slit extending in the longitudinal direction at the excretory part facing part that is disposed to face the excretion part of the wearer when worn, and the longitudinal slit includes the blood aggregating agent.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 7>, wherein the absorbent article penetrates through the absorbent sheet closest to the skin.
  • the absorbent body has a longitudinal slit extending in the longitudinal direction at the excretory part facing part that is disposed to face the excretion part of the wearer when worn, and the width of the longitudinal slit is 0.1 mm to 1 mm, preferably 0.
  • the absorbent body has a longitudinal slit extending in the longitudinal direction in the excretory part facing part that is disposed to face the excretion part of the wearer when worn, and the length when viewed in plan is 10 mm or more and 35 mm or less.
  • the absorbent body has a longitudinal slit extending in the longitudinal direction at the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and the longitudinal slits are adjacent to each other in the lateral direction and exist in a plurality of rows.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 10>, wherein the interval between the longitudinal slits adjacent in the lateral direction is 3 mm or more and 20 mm or less, preferably 7 mm or more and 15 mm or less.
  • the absorbent body has a longitudinal slit extending in the longitudinal direction in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and there are a plurality of the longitudinal slits dispersed in the longitudinal direction.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 11>.
  • the absorber comprises an absorbent sheet,
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the basis weight of the blood aggregating agent in the excretory part facing part is greater than the basis weight of the blood aggregating agent in the peripheral part of the excretion part facing part, according to any one of the above items ⁇ 1> to ⁇ 12>.
  • Absorbent article is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the basis weight of the blood aggregating agent in the excretory part facing part is greater than the basis weight of the blood aggregating agent in the peripheral part of the excretion part facing part, according to any one of the above items ⁇ 1> to ⁇ 12>.
  • the absorber comprises an absorbent sheet
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the absorbent article according to any one of ⁇ 1> to ⁇ 13>, wherein the central absorbent sheet has a multilayer structure in which a plurality of the absorbent sheets are overlapped.
  • the absorber comprises an absorbent sheet
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the central absorbent sheet has a portion in which the arrangement of the polymer rich region and the hydrophilic fiber rich region of the absorbent sheet in the thickness direction is reversed between adjacent absorbent sheets in the thickness direction.
  • the absorber comprises an absorbent sheet
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet
  • the central absorbent sheet has a structure in which one absorbent sheet is bent so as to have at least a three-layer structure, of which the uppermost layer located closest to the skin contact surface side and the thickness direction
  • the absorptivity according to any one of ⁇ 1> to ⁇ 15>, wherein the second layer adjacent to the uppermost layer is the same in the arrangement in the thickness direction of the hydrophilic fiber-rich region and the polymer-rich region. Goods.
  • the absorber comprises an absorbent sheet
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the absorbent article according to any one of ⁇ 1> to ⁇ 16>, wherein the blood aggregating agent is contained only in the central absorbent sheet.
  • the absorber comprises an absorbent sheet
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the absorbent article according to any one of ⁇ 1> to ⁇ 17>, wherein the blood aggregating agent is contained only in the main body absorbent sheet.
  • the absorber comprises an absorbent sheet
  • the absorbent sheet is composed of a central absorbent sheet disposed in the excretory part facing part disposed opposite to the excretion part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet,
  • the absorbent article according to any one of ⁇ 1> to ⁇ 17>, wherein the blood aggregating agent is contained in the central absorbent sheet and the main body absorbent sheet.
  • the absorbent body is made of an absorbent sheet, and the absorbent sheet located closest to the skin contact surface side has a hydrophilic fiber rich region on the skin contact surface side and a polymer rich region on the non-skin when viewed in the thickness direction.
  • ⁇ 21> Any one of ⁇ 1> to ⁇ 20>, wherein a second sheet made of a nonwoven fabric is disposed between the top sheet and the absorber, and the second sheet does not contain the blood aggregating agent.
  • the blood coagulant is a cationic polymer, and the molecular weight of the cationic polymer is 2000 or more and 10 million or less, preferably 2000 or more and 5 million or less, more preferably 2000 or more and 3 million or less, and still more preferably 1
  • the absorbent article according to any one of ⁇ 1> to ⁇ 21> which is from 10,000 to 3,000,000.
  • the amount of the blood coagulation agent is preferably 1 g / m 2 or more 20 g / m 2 or less, more preferably 3 g / m 2 or more 15 g / m 2 or less, more preferably is 5 g / m 2 or more 10 g / m 2 or less.
  • the blood coagulant is a water-soluble cationic polymer
  • the water-soluble cationic polymer has a structure having a main chain and a side chain bonded thereto, and has a molecular weight of 2000 or more
  • the water-soluble cationic polymer Is a quaternary ammonium salt homopolymer having a repeating unit represented by the following formula 1, or a repeating unit represented by the following formula 1 and a repeating unit represented by the following formula 2:
  • a quaternary ammonium salt copolymer having the main chain of the water-soluble cationic polymer and the side chain bonded at one point, and the side chain having a quaternary ammonium moiety.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 23> which is for blood absorption to which a certain water-soluble cationic polymer is applied.
  • a certain water-soluble cationic polymer As the blood coagulant, 1 g / m of a water-soluble cationic polymer made of a quaternary ammonium salt homopolymer or a quaternary ammonium salt copolymer having a streaming potential of 1500 ⁇ eq / L or more and a molecular weight of 2000 or more.
  • the blood coagulant is a water-soluble cationic polymer, and the water-soluble cationic polymer has a quaternary ammonium salt homopolymer or a quaternary ammonium salt copolymer having a main chain and a side chain bonded thereto.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 25>, which has a structure, wherein the main chain and the side chain are bonded at one point.
  • the blood coagulant includes a water-soluble cationic polymer having a molecular weight of 2000 or more, and the cationic polymer has an inorganic value / organic value which is a ratio of an inorganic value to an organic value of 0.
  • ⁇ 1> to ⁇ 25 wherein the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.
  • the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.
  • ⁇ 28> The absorbent article according to any one of ⁇ 1> to ⁇ 27>, wherein the absorbent article is a sanitary napkin.
  • Example 1 A sanitary napkin having the same basic structure as the sanitary napkin 1 shown in FIGS. 1 to 3 having the absorbent body shown in FIGS. 4 and 5 was produced, and this was used as a sample of Example 1.
  • As the surface sheet an air-through nonwoven fabric sheet having a single layer structure was used. The surface sheet had a basis weight of 25 g / m 2 . A moisture-permeable resin film was used as the back sheet.
  • As the second sheet a point bond air-through nonwoven fabric having a basis weight of 25 g / m 2 was used.
  • an absorptive sheet which comprises an absorber it created according to Example 2 of patent 2963647.
  • a cationic polymer contained in the blood coagulant trade name Marcoat 100 (weight average molecular weight: 150,000, IOB value 2.10, flow potential 7488 ⁇ eq / L) manufactured by Nippon Lubrizol Co., Ltd. was used. And, like the absorbent body shown in FIG. 4, only the central absorbent sheet 402 that forms a three-layer structure composed of the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b is used for the blood aggregating agent 43. Is arranged.
  • the blood aggregating agent 43 is not disposed on the main body absorbent sheet 401 that forms a two-layer structure including the front surface side absorbent sheet 401a and the back surface side absorbent sheet 401b.
  • the basis weight of the cationic polymer applied to the absorbent sheet was 1.5 g / m 2 for each of the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b. Further, a longitudinal slit was arranged in the absorber as shown in FIG.
  • Example 2 As a cationic polymer contained in the blood coagulant, trade name Marcoat 106 (weight average molecular weight: 15,000, IOB value 2.10, flow potential 7345 ⁇ eq / L) manufactured by Nippon Lubrizol Co., Ltd. was used. The basis weight of the cationic polymer applied to the absorbent sheet was 1.5 g / m 2 . Otherwise, a sanitary napkin was prepared in the same manner as in Example 1.
  • Example 3 A sanitary napkin was prepared in the same manner as in Example 2 except that the absorbent shown in FIG. 6 was used. That is, as in Example 2, as the cationic polymer contained in the blood coagulant, the trade name Marcoat 106 manufactured by Nippon Lubrizol Co., Ltd. was used. As in the absorbent body shown in FIG. 6, the blood aggregating agent 43 is arranged only on the main body absorbent sheet 401 that forms a two-layer structure composed of the front-side absorbent sheet 401 a and the back-side absorbent sheet 401 b. ing.
  • the blood aggregating agent 43 is not disposed on the central absorbent sheet 402 that forms a three-layer structure including the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b.
  • the basis weight of the cationic polymer applied to the absorbent sheet was 1.5 g / m 2 for each of the front-side absorbent sheet 401a and the back-side absorbent sheet 401b.
  • Example 4 A sanitary napkin was prepared in the same manner as in Example 2 except that the absorbent shown in FIG. 7 was used. That is, as in Example 2, as the cationic polymer contained in the blood coagulant, the trade name Marcoat 106 manufactured by Nippon Lubrizol Co., Ltd. was used. As in the absorbent body shown in FIG. 7, the absorbent body has a blood aggregating agent 43 disposed on a main body absorbent sheet 401 that forms a two-layer structure composed of a front surface side absorbent sheet 401a and a back surface side absorbent sheet 401b. Yes.
  • a blood aggregating agent 43 is disposed on a central absorbent sheet 402 that forms a three-layer structure including an upper absorbent sheet 402a, an intermediate absorbent sheet 402c, and a lower absorbent sheet 402b.
  • the basis weight of the cationic polymer applied to the absorbent sheet was 1.5 g / m 2 , respectively.
  • the third and subsequent liquid injections are repeated 3 minutes after the liquid injection, and 2 g of pseudo blood is repeatedly injected.
  • the simulated blood was measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) as described in this specification.
  • the blood cell / plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Laboratories Co., Ltd.) was prepared so that the viscosity obtained was 8 mPa ⁇ s.
  • Example and Comparative Example were placed horizontally for evaluation.
  • An acrylic plate with an elliptic cylinder with an inlet having a diameter of 3 cm is stacked on each sample of the example and the comparative example, and the sample is placed on the discharge portion facing portion (position 40 mm from the front end in the longitudinal direction of the sample). Simulated blood was injected from the inlet. After injection, the state was held for 3 minutes. Next, the elliptical acrylic plate was removed, and a weight was placed on the surface of the topsheet so that the pressure was 18 kPa and pressurized for 1 minute (first time).
  • the above-mentioned acrylic plate was overlaid again on the sample after the test, and after 3 minutes from the first injection, 3 g of pseudo blood was added again from the injection port and injected.
  • the injection position of the simulated blood into each sample of the example and the comparative example was the same as the position where the first 3 g was injected. From the second time onward, the same operation as the first time was repeated, and when the liquid oozed out from the wing part of each sample of Examples and Comparative Examples, the operation was finished and the static maximum absorption amount was obtained.
  • the liquid-absorbing paper (length 170 mm, width 70 mm, basis weight 35 g / weight) pre-weighed in the liquid absorption part of the sample (the part into which the liquid was poured in the measurement of the liquid absorption time).
  • 10 sheets of tissue paper (cm 2 ) were stacked on the surface of the sample, and the sample was quickly attached to the crotch part of the shorts and attached to the dynamic walking model and allowed to walk for 2 minutes. After walking, the movement of the model was stopped, the absorbent paper was taken out and weighed, and the amount of liquid (g) absorbed by the absorbent paper was calculated. Each sample was measured three times, and the average value was taken as the dynamic liquid return amount of the sample.
  • the sanitary napkins of Examples 1 to 4 both had a larger dynamic maximum absorption amount and a static maximum absorption amount than the sanitary napkin of Comparative Example 1. .
  • the sanitary napkins of Examples 1 to 4 had a smaller dynamic diffusion area on the surface sheet and a smaller amount of dynamic liquid return than the sanitary napkins of Comparative Example 1. Therefore, the sanitary napkins of Examples 1 to 4 can absorb blood more effectively than the sanitary napkin of Comparative Example 1, and it is difficult for the liquid to return, and spot absorption is performed without spreading the blood. I can expect that.
  • blood can be effectively absorbed into the superabsorbent polymer, and it is difficult for the liquid to return, and spot absorption can be performed without spreading the blood.

Abstract

La présente invention concerne un article absorbant (1) qui est pourvu d'un corps absorbant (4) qui est capable d'absorber du sang, le corps absorbant (4) contenant un polymère à pouvoir absorbant élevé (41), de la pâte cellulosique (42) et un agent de coagulation sanguine (43). Le corps absorbant (4), observé en section transversale, présente une région riche en polymère (PT) dans laquelle le rapport en masse du polymère à pouvoir absorbant élevé (41) par rapport au total de la masse de la pâte cellulosique (42) et de la masse du polymère à pouvoir absorbant élevé (41) est relativement élevé, et une région riche en pâte cellulosique (FT) dans laquelle le rapport en masse mentionné ci-dessus est relativement faible. Une quantité de l'agent de coagulation sanguine (43) présente dans la région riche en polymère (PT) est plus élevée que celle dans la région riche en pâte cellulosique (FT).
PCT/JP2016/087722 2015-12-22 2016-12-19 Article absorbant WO2017110716A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680069797.8A CN108366892B (zh) 2015-12-22 2016-12-19 吸收性物品

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015-250587 2015-12-22
JP2015250587 2015-12-22
JP2016-111716 2016-06-03
JP2016111716A JP6279014B2 (ja) 2015-12-22 2016-06-03 吸収性物品

Publications (1)

Publication Number Publication Date
WO2017110716A1 true WO2017110716A1 (fr) 2017-06-29

Family

ID=59090343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/087722 WO2017110716A1 (fr) 2015-12-22 2016-12-19 Article absorbant

Country Status (1)

Country Link
WO (1) WO2017110716A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019093267A1 (fr) * 2017-11-08 2019-05-16 花王株式会社 Article absorbant

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JPH0483230U (fr) * 1990-11-30 1992-07-20
JPH0483326U (fr) * 1990-11-30 1992-07-20
WO2002059214A1 (fr) * 2001-01-26 2002-08-01 Nippon Shokubai Co., Ltd. Agent d'absorption d'eau et procede de production correspondant, et article absorbant l'eau
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2003519245A (ja) * 1999-04-16 2003-06-17 キンバリー クラーク ワールドワイド インコーポレイテッド 超吸収体含有複合物
JP2010514489A (ja) * 2007-01-12 2010-05-06 ザ プロクター アンド ギャンブル カンパニー 改善された構造を有する吸収性コア
US20100174260A1 (en) * 2000-05-26 2010-07-08 Kimberly-Clark Worldwide, Inc. Menses Specific Absorbent Systems
WO2015029587A1 (fr) * 2013-09-02 2015-03-05 花王株式会社 Produit absorbant
WO2016093233A1 (fr) * 2014-12-09 2016-06-16 花王株式会社 Produit sanitaire et agent de traitement de produit sanitaire

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JPH0483230U (fr) * 1990-11-30 1992-07-20
JPH0483326U (fr) * 1990-11-30 1992-07-20
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2003519245A (ja) * 1999-04-16 2003-06-17 キンバリー クラーク ワールドワイド インコーポレイテッド 超吸収体含有複合物
US20100174260A1 (en) * 2000-05-26 2010-07-08 Kimberly-Clark Worldwide, Inc. Menses Specific Absorbent Systems
WO2002059214A1 (fr) * 2001-01-26 2002-08-01 Nippon Shokubai Co., Ltd. Agent d'absorption d'eau et procede de production correspondant, et article absorbant l'eau
JP2010514489A (ja) * 2007-01-12 2010-05-06 ザ プロクター アンド ギャンブル カンパニー 改善された構造を有する吸収性コア
WO2015029587A1 (fr) * 2013-09-02 2015-03-05 花王株式会社 Produit absorbant
WO2016093233A1 (fr) * 2014-12-09 2016-06-16 花王株式会社 Produit sanitaire et agent de traitement de produit sanitaire

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019093267A1 (fr) * 2017-11-08 2019-05-16 花王株式会社 Article absorbant
JP2019084139A (ja) * 2017-11-08 2019-06-06 花王株式会社 吸収性物品
TWI781245B (zh) * 2017-11-08 2022-10-21 日商花王股份有限公司 吸收性物品及吸收性物品之製造方法

Similar Documents

Publication Publication Date Title
CN108882999B (zh) 吸收性物品
JP2017217071A (ja) 生理用吸収性物品
JP6279014B2 (ja) 吸収性物品
CN108778208B (zh) 吸收性物品
JP6279015B2 (ja) 吸収性物品
JP6259540B2 (ja) 生理用吸収性物品
JP2018007705A (ja) 生理用吸収性物品
JP6706147B2 (ja) 生理用吸収性物品
JP2017217078A (ja) 吸収性物品
WO2017209076A1 (fr) Article absorbant hygiénique
WO2017110716A1 (fr) Article absorbant
JP6259539B2 (ja) 生理用吸収性物品
JP3222476U (ja) 生理用吸収性物品
WO2017110717A1 (fr) Article absorbant
JP6762142B2 (ja) 吸収性物品
WO2017209069A1 (fr) Article absorbant
WO2017209075A1 (fr) Article absorbant hygiénique
JP6757601B2 (ja) 生理用吸収性物品
JP6220947B1 (ja) 生理用品
TW201801690A (zh) 吸收性物品
JP2017217464A (ja) 吸収性物品
JP6714435B2 (ja) 生理用吸収性物品
WO2017209072A1 (fr) Article absorbant
JP2018007706A (ja) 生理用吸収性物品
JP2017217104A (ja) 吸収性物品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16878605

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16878605

Country of ref document: EP

Kind code of ref document: A1